Foresee Pharmaceuticals Announces Completion of Casppian Phase 3 Study with Last Patient Last Visit and Confirms Topline Results: 94% of Patients Achieve LH Suppression with 6-Month Dosing Interval of Leuprolide Mesylate, also the acceptance of Casppian Study for Presentation at Endocrine Society, ENDO 2026 Medical Conference, as a Potential New Six-Month Treatment Option for Central Precocious Puberty

Foresee Pharmaceuticals Announces Completion of Casppian Phase 3 Study with Last Patient Last Visit and Confirms Topline Results: 94% of Patients Achieve LH Suppression with 6-Month Dosing Interval of Leuprolide Mesylate, also the acceptance of Casppian Study for Presentation at Endocrine Society, ENDO 2026 Medical Conference, as a Potential New Six-Month Treatment Option for Central Precocious Puberty

PR Newswire

TAIPEI, May 27, 2026

Foresee outlines plan for NDA submission to FDA and other global health authorities by late 2026Plan for NDA Submission and Global Regulatory FilingsThe Casppian Phase 3 Study was accepted for Presentation at the Endocrine Society, ENDO 2026: A Potential New Six-Month Treatment Option for Central Precocious PubertyTAIPEI, May 27, 2026 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announced the successful completion of the Casppian Phase 3 clinical trial, with the Last Patient Last Visit (LPLV) now concluded. This milestone follows the previously reported positive topline results demonstrating that FP-001 42 mg (leuprolide mesylate), an investigational, sustained-release GnRH agonist administered every six months, met its primary efficacy endpoint in children with Central Precocious Puberty (CPP).